Relapse Clinical Trials in Tianjin, Tianjin Municipality
19 recruitingTianjin, Tianjin Municipality, China
Showing 1–19 of 19 trials
Recruiting
Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Beijing InnoCare Pharma Tech Co., Ltd.75 enrolled29 locationsNCT07082686
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
BeOne Medicines246 enrolled83 locationsNCT04973605
Recruiting
Phase 1
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Jiangsu Simcere Pharmaceutical Co., Ltd.130 enrolled11 locationsNCT06375044
Recruiting
Phase 3
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.228 enrolled1 locationNCT07138209
Recruiting
Phase 2
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.100 enrolled15 locationsNCT07188610
Recruiting
Phase 1Phase 2
A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Nanjing Leads Biolabs Co.,Ltd342 enrolled26 locationsNCT06049290
Recruiting
Phase 3
A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis
TJ Biopharma Co., Ltd.30 enrolled15 locationsNCT07208058
Recruiting
Not Applicable
CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors
Relapsed and Refractory CD5 Hematological Tumors
Institute of Hematology & Blood Diseases Hospital, China18 enrolled1 locationNCT07234110
Recruiting
Phase 1
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Sichuan Baili Pharmaceutical Co., Ltd.130 enrolled8 locationsNCT05924750
Recruiting
Phase 2
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.100 enrolled11 locationsNCT04684147
Recruiting
Phase 2
Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Institute of Hematology & Blood Diseases Hospital, China41 enrolled3 locationsNCT06224257
Recruiting
Phase 1
CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia
RelapseRefractorySevere Aplastic Anemia
Institute of Hematology & Blood Diseases Hospital, China15 enrolled1 locationNCT06622694
Recruiting
Phase 3
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
Relapsed/Refractory Multiple Myeloma
Hangzhou Sumgen Biotech Co., Ltd.360 enrolled12 locationsNCT06508983
Recruiting
Phase 2
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaRelapsed Pediatric ALL
Chongqing Precision Biotech Co., Ltd100 enrolled10 locationsNCT05334823
Recruiting
Phase 2
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
Relapsed/Refractory Large B-Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China89 enrolled1 locationNCT06489808
Recruiting
Phase 2
VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT
Relapse Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China30 enrolled1 locationNCT06447090
Recruiting
Phase 1
A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Nanjing Chia-tai Tianqing Pharmaceutical72 enrolled1 locationNCT06049667
Recruiting
Phase 1
TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
B7-H3-positive Relapsed/ Refractory Neuroblastoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.24 enrolled2 locationsNCT05562024